HIV type 1-specific inter- and intrasubtype cellular immune responses in HIV type 1-infected Ugandans

AIDS Research and Human Retroviruses

Volumn 20, Issue 7, 2004, Pages 763-771

  Rutebemberwa, Alleluiah ^a   Auma, Betty ^b   Gilmour, Jill ^c   Jones, Gareth ^c   Yirrell, David ^d   Rowland, Samantha ^c   Imami, Nesrina ^c   Watera, Christine ^b   Kaleebu, Pontiano ^b   Whitworth, James ^b   Gotch, Frances ^c  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; POL PROTEIN; VIRUS ENVELOPE PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINIA VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, VIRAL; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; RECOMBINATION, GENETIC; UGANDA; VACCINIA VIRUS; VIRAL STRUCTURAL PROTEINS;

EID: 3843104693     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041524643     Document Type: Article

References (39)

1. UNAIDS/WHO global report December, 2001.
2. Gao F, Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, Beddows S, Weber J, Sharp PM, Shaw GM, Hahn B, and the WHO and NIAID Networks for HIV Isolation and Characterization: Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996;70:1651-1667.
3. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, Fultz PN, Girard M, Shaw GM, Hahn BH, and Sharp PM: The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996;70:7013-7029.
4. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, and Miedema F: Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
5. + lymphocyte counts: Immunologic and virologic characteristics. J Infect Dis 1991; 163:959-965.
6. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, Pialoux G, Feuillie V, Mollereau M, Chamaret S, et al.: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995; 11:903-907.
7. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
8. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, and Whittle H: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
9. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, Rutherford J, Njagi E, Mwangi F, Rostron T, Onyango J, Oyugi J, MacDonald KS, Bwayo JJ, and Plummer FA: New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001;79 (1-2):3-13.
10. + T-cell immunity to HIV infection. Clin Lab Med 2002;22:773-797.
11. Makedonas G, Bruneau J, Lin H, Sekaly RP, Lamothe F, and Bernard NF: HIV-specific CD8 T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity. AIDS 2002;16(12):1595-1602.
12. Voelker R: HIV vaccine trial in Africa. JAMA 1999;281:889.
13. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
14. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290-298.
15. Gorse GJ, Patel GB, and Belshe RB: HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Hum Retroviruses 2001;17: 1175-1189.
16. Hanke T and McMichael A: Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett 1999;66:177-181.
17. Girard M, Habel A, and Chanel C: New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview. CR Acad Sci III 1999;322:959-966.
18. McAdam S, Kaleebu P, Krausa P, Goulder P, French N, Collin B, Blanchard T, Whitworth J, McMichael A, and Gotch F: Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 1998;12:571-579.
19. Cao H, Kanki P, Sankale JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, and Walker BD: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
20. Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, Kanki P, Ellner J, and Walker BD: Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials in Uganda. J Infect Dis 2000;182:1350-1356.
21. Durali D, Morvan J, Letourneur F, Schmitt D, Guegan N, Dalod M, Saragosti S, Sicard D, Levy JP, and Gomard E: Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 1998;72:3547-3553.
22. Dorrell L, Willcox BE, Jones EY, Gillespie G, Njai H, Sabally S, Jaye A, DeGleria K, Rostron T, Lepin E, McMichael A, Whittle H, and Rowland-Jones S: Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53. Eur J Immunol 2001;31:1747-1756.
23. + memory T cells. J Exp Med 1997;186:859-865.
24. Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, McMichael AJ, Cox WI, Steinman RM, Nixon D, and Bhardwaj N: A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999;13:767-777.
25. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, Blanchard T, Ariyoshi K, Oyugi J, Ngugi E, Bwayo J, MacDonald KS, McMichael AJ, and Plummer FA: Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765.
26. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T, Thior I, Ndung'u T, Marlink R, Lee TH, and Essex M: Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001;75: 9210-9228.
27. Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SA, McIntosh K, Walker BD, and Goulder PJ: Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay. J Virol 2000;74:8541-8549.
28. Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, and Walker BD: Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol 2001;75: 1339-1347.
29. Krausa P, McAdam S, Bunce M, Whitworth J, Biryahwaho B, French N, Tugume B, Gilks C, and Gotch F: HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Exp Clin Immunogenet 1999;16:17-25.
30. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, and Welsh KI: Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995;46:355-367.
31. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rubsamen-Waigmann H, and Mullins JI: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
32. Yirrell DL, Pickering H, Palmarini G, Hamilton L, Rutebemerwa A, Biryahwaho B, Whitworth J, and Brown AJ: Molecular epidemiological analysis of HIV in sexual networks in Uganda. AIDS 1998;12:285-290.
33. Kaleebu P, Yirrell D, French N, Lyagoba F, Rutebemerwa A, Cheingsong-Popov R, Gilks C, Biryahwaho B, Weber J, and Whitworth J: An improved algorithm for determining HIV type 1 subtypes in a primary laboratory in Uganda. AIDS Res Hum Retroviruses 2000;16:621-625.
34. Smith SW, Overbeek R, Woese CR, Gilbert W, and Gillevet PM: The genetic data environment an expandable GUI for multiple sequence analysis. Comput Appl Biosci 1994;10:671-675.
35. Van de Peer Y and De Wachter R: TREECON for Windows: A software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 1994;10:569-570.
36. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16:111-120.
37. Betts MR, Casazza JP, Patterson BA, Waldrop S, Trigona W, Fu TM, Kern F, Picker LJ, and Koup RA: Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol 2000;74:9144-9151.
38. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, and Desrosiers RC: Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999;73: 8356-8363.
39. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, Glickman R, Yang J, Montefiori DC, Montelaro R, Wyand MS, and Desrosiers RC: Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999;73:4952-4961.